Abstract

ABSTRACT:
BACKGROUND:
Hepatitis B virus (HBV) infection is a major public health problem. Successful clearance of the virus depends on a complex interaction between the virus and the host immune response.
OBJECTIVE:
This study was designed to estimation granulocyte macrophage-colony stimulating factor (GM-CSF) in HBV infected patients and individuals vaccinated with recombinant HB vaccine.
METHODS:
Study groups were classified into patient group 31(15 acute (AH) and 16 chronic (CH)), 33 vaccinated group (20 responder (RD) and 13 Non-responder (NRD)) and 16 healthy control (HC) during May to November 2007. Blood samples were taken from patients and hospitals staffs to detection hepatitis B surface antigen(HBsAg), anti-hepatitis B core antibody(IgM)(Anti-HBc Ab(IgM), anti hepatitis B surface antibody) (Anti-HBs Ab), GM-CSF level in serum by enzyme linked immunosorbent assay (ELISA) test.
RESULTS:
A highly significant elevation (p<0.001) of GM-CSF level was reported in AH patients compared to the CH patients and HN controls, according to F-test, while in CH patients the elevation was not significant as compared to HN control (p>0.05) according to LSD- test. The level of GM-CSF also significantly higher (p<0.05) in RD at age ≥30 years than NRD and HN groups by F-test. Also a significant differences was recorded when compared between HN versus RD and RD versus NRD (P<0.027) and (P<0.023) respectively.
CONCLUSION:
In this study highly significant elevation of GM-CSF levels was observed in AH patients compared with CH patients and healthy control. GM-CSF level also significantly higher in RD at age ≥30 years than NRD and HN group